Back to Feed
ClinicalTrials.gov|Clinical Trial
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Novartis Pharmaceuticals
Abstract
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136. Phase: PHASE1, PHASE2 Status: NOT_YET_RECRUITING Conditions: Extensive-stage Small Cell Lung Cancer (ES-SCLC) Interventions: DJI136
Keywords
Extensive-stage Small Cell Lung Cancer (ES-SCLC)